Literature DB >> 25047362

Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention.

D Gareth Evans1, Adam R Brentnall2, Michelle Harvie3, Sarah Dawe3, Jamie C Sergeant4, Paula Stavrinos3, Susan Astley5, Mary Wilson3, John Ainsworth6, Jack Cuzick2, Iain Buchan6, Louise S Donnelly3, Anthony Howell7.   

Abstract

In the United Kingdom, women at moderate and high risk of breast cancer between the ages of 40 and 49 years are eligible for annual mammographic screening and preventive therapy with tamoxifen. Here, we estimate the numbers of women in a population eligible for this service and the proportion of breast cancers detected in this group compared with the whole population. Women <50 attending for mammographic screening in the National Health Service Breast Screening Programme (NHSBSP) completed a risk questionnaire. The proportion at moderate and high risk according to National Institute of Health Care Excellence (NICE) guidelines was estimated. An estimate was also made using a different model of risk estimation (Tyrer-Cuzick). The numbers of cancers detected in the moderate/high risk groups were compared with numbers detected in the whole population. Completed questionnaires were available for 4,360 women between ages 46 and 49 years. Thirty women [0.7%; 95% confidence interval (CI), 0.5-1.0%] were at high risk and 130 (3.0%, 2.5-3.5%) were at moderate risk according to NICE guidelines. Thirty-seven cancers were detected by mammography in the whole group. Five of these were found in the moderate-/high-risk group giving a 3.2-fold increase in detection compared with the standard risk group. More women were assigned to the moderate- or high-risk group using the Tyrer-Cuzick model (N = 384), but the numbers of cancers in this group were not appreciably increased (N = 8). Systematic assessment of family history in primary care or through population-based screening will identify appreciable numbers of women in their forties, eligible for additional surveillance and chemoprevention. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25047362     DOI: 10.1158/1940-6207.CAPR-14-0037

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  15 in total

1.  Evaluation of 2 breast cancer risk models in a benign breast disease cohort.

Authors:  Ryan D Frank; Stacey J Winham; Robert A Vierkant; Marlene H Frost; Derek C Radisky; Karthik Ghosh; Kathleen R Brandt; Mark E Sherman; Daniel W Visscher; Lynn C Hartmann; Amy C Degnim; Celine M Vachon
Journal:  Cancer       Date:  2018-06-22       Impact factor: 6.860

2.  Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.

Authors:  Jack Cuzick; Adam R Brentnall; Corrinne Segal; Helen Byers; Caroline Reuter; Simone Detre; Elena Lopez-Knowles; Ivana Sestak; Anthony Howell; Trevor J Powles; William G Newman; Mitchell Dowsett
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

3.  Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis.

Authors:  Helen J Curtis; Alex J Walker; Ben Goldacre
Journal:  Br J Cancer       Date:  2018-04-23       Impact factor: 7.640

4.  What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420).

Authors:  David P French; Susan Astley; Adam R Brentnall; Jack Cuzick; Richard Dobrashian; Stephen W Duffy; Louise S Gorman; Elaine F Harkness; Fiona Harrison; Michelle Harvie; Anthony Howell; Andrew Jerrison; Matthew Machin; Anthony J Maxwell; Lorna McWilliams; Katherine Payne; Nadeem Qureshi; Helen Ruane; Sarah Sampson; Paula Stavrinos; Emma Thorpe; Fiona Ulph; Tjeerd van Staa; Victoria Woof; D Gareth Evans
Journal:  BMC Cancer       Date:  2020-06-18       Impact factor: 4.430

5.  Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer.

Authors:  D G Evans; S Thomas; J Caunt; A Burch; A R Brentnall; L Roberts; A Howell; M Wilson; R Fox; S Hillier; D M Sibbering; S Moss; M G Wallis; D M Eccles; S Duffy
Journal:  EClinicalMedicine       Date:  2019-01

6.  Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort.

Authors:  Adam R Brentnall; Elaine F Harkness; Susan M Astley; Louise S Donnelly; Paula Stavrinos; Sarah Sampson; Lynne Fox; Jamie C Sergeant; Michelle N Harvie; Mary Wilson; Ursula Beetles; Soujanya Gadde; Yit Lim; Anil Jain; Sara Bundred; Nicola Barr; Valerie Reece; Anthony Howell; Jack Cuzick; D Gareth R Evans
Journal:  Breast Cancer Res       Date:  2015-12-01       Impact factor: 6.466

7.  Can the breast screening appointment be used to provide risk assessment and prevention advice?

Authors:  D Gareth Evans; Anthony Howell
Journal:  Breast Cancer Res       Date:  2015-07-09       Impact factor: 6.466

8.  Breast cancer risk feedback to women in the UK NHS breast screening population.

Authors:  D Gareth R Evans; Louise S Donnelly; Elaine F Harkness; Susan M Astley; Paula Stavrinos; Sarah Dawe; Donna Watterson; Lynne Fox; Jamie C Sergeant; Sarah Ingham; Michelle N Harvie; Mary Wilson; Ursula Beetles; Iain Buchan; Adam R Brentnall; David P French; Jack Cuzick; Anthony Howell
Journal:  Br J Cancer       Date:  2016-03-29       Impact factor: 7.640

9.  Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care.

Authors:  Siang Ing Lee; Nadeem Qureshi; Brittany Dutton; Joe Kai; Stephen Weng
Journal:  J Community Genet       Date:  2020-01-22

10.  Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials.

Authors:  Michelle Harvie; Mary Pegington; David French; Grace Cooper; Sarah McDiarmid; Anthony Howell; Louise Donnelly; Helen Ruane; Katharine Sellers; Philip Foden; D Gareth Evans
Journal:  BMC Cancer       Date:  2019-12-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.